George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
100% Seaking1, we know these vaccines work, a small tweak is trivial compared to developing them in the first place, and tweaks for different strains do not need a full round of clinical testing, only efficacy testing (ie phase 3)
Just so we're clear, the dividend will be cut as part of the split, but GSK share holders will get their shares split across the 2 businesses anyway and the share price will also be cut, so i don't see why the potential for the dividend to be split is an issue.Buy now and you get 6% annual roi on dividends alone which isn't bad.
Well, splitting hairs you would have had Glaxo Wellcome or SmithKline Beecham shares before 19 years ago.
However you split it, i don't think now (well, the now when the price was over £16) is a time to buy. now is a time to sell or hold. Hold if you are holding GSK shares for the long haul as you are, or sell if you are playing the ups and downs. I wouldn't buy over 1580 personally.